Condition: Postpartum Preeclampsia · Sponsor: Medical College of Wisconsin
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.
This description comes directly from the study's public registry record.
Alyssa Hernandez, DO · 4148055285 · alyhernandez@mcw.edu
Always discuss trial participation with your own doctor first.
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Active Not Recruiting |
| Dhulikhel Hospital | Dhulikhel, Nepal | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07185204